about
Complement regulation of T-cell alloimmunityThe Impact of Histologic Variants on FSGS OutcomesImmunosuppressive effects of erythropoietin on human alloreactive T cellsRefractory focal segmental glomerulosclerosis in the adult: complete and sustained remissions of two episodes of nephrotic syndrome after a single dose of rituximabImmune cell-derived C3a and C5a costimulate human T cell alloimmunity.Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy.Low-density array PCR analysis of reperfusion biopsies: an adjunct to histological analysis.The Kidney Donor Profile Index (KDPI) of marginal donors allocated by standardized pretransplant donor biopsy assessment: distribution and association with graft outcomesDoes remission of renal disease associated with antihypertensive treatment exist?Latest treatment strategies for membranous nephropathy.Intensified inhibition of renin-angiotensin system: a way to improve renal protection?Pathophysiology of proteinuria and its value as an outcome measure in chronic kidney diseaseSirolimus to replace calcineurin inhibitors? Too early yet.Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?Targeting the renin angiotensin system in dialysis patients.Mechanisms and treatment of CKD.Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases.Complement as a multifaceted modulator of kidney transplant injury.Monitoring T cell alloreactivity.Looking into the Graft without a Biopsy: Biomarkers of Acute Rejection in Renal Transplantation.Monitoring alloimmune response in kidney transplantation.New biologics in the treatment of rare glomerular diseases of childhood.A step towards clinical application of acellular matrix: A clue from macrophage polarization.Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.Complement in Non-Antibody-Mediated Kidney Diseases.The role of renin angiotensin system inhibition in kidney repair.ACTH action on podocytes: mystery solved?Cutting edge: Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells.Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: A 3-year prospective study.Corrigendum. Complement as a multifaceted modulator of kidney transplant injurySirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury.Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival.Mycophenolate mofetil versus azathioprine in organ transplantation.Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial.Thrice-weekly in-center nocturnal hemodialysis: an effective strategy to optimize chronic dialysis therapy.Proteinuria: Increased angiotensin-receptor blocking is not the first option.Effect of a novel immunosuppressant, ST1959, on the immune system and renal allograft survival in rats.Regenerative immunology: the immunological reaction to biomaterials.Rapid Biolayer Interferometry Measurements of Urinary CXCL9 to Detect Cellular Infiltrates Noninvasively After Kidney Transplantation.Achieving remission of proteinuria in childhood CKD.
P50
Q26823956-33694A12-7BE5-442C-A924-ADBAFD81293AQ27011243-C479F6E2-65BB-4117-AE7F-7583E7A96B86Q34103447-885F23CB-4BB5-44C1-97A2-D374683183E2Q34130591-7B47F17C-E473-4B18-8AD3-E98A20386735Q34370940-72A2A27D-30D6-44C5-AF8E-63F6CC014133Q34656882-BCB52CA1-EDDE-4983-9F28-843EBF4BC720Q35025490-B7035F50-30F0-4B00-96CC-B691BBF786B5Q35448662-908258BF-EEA1-42D2-AE04-2A7AE5207A1BQ36794965-B2985C25-4455-46F0-89D0-78EB0BE1CD85Q37013035-45BCCDD2-91B4-4736-9F4D-1037EE01EF60Q37051491-F3C637C6-0280-424F-BC52-2A7FE5DE4E13Q37219039-EA96AC8A-009A-47EC-9247-A10495A5ED31Q37442119-5479BA0C-5BB5-47CA-98C9-14273A3C807CQ37709432-09CC7D42-DD37-43C4-9328-C959B42D724EQ37891151-457C1987-6FE9-4031-9E99-FC6B33A58BA6Q38055716-F00E8D8F-6237-49FA-A90C-74D3235CE036Q38209548-9318D0B6-B436-4917-B928-317EFB9A9E21Q38217273-1081284F-8248-49CD-83A6-70C6266D7333Q38283086-B5EB55EF-E034-4B5E-8C19-1F6548A71834Q38680129-86DFEA2F-BFAB-41C8-AEC7-ED1B5D9A6445Q38849321-D7BE3802-B9A3-469A-B686-71CD17244932Q39272009-0F379FB4-D289-49EE-9DF2-F21CA0822551Q39439987-8643F7C6-2D85-4DD8-A61D-C80269D12BA1Q40441736-B52912ED-2212-4649-A80A-A6A656CF7A2AQ40986583-EF2EA1AC-1178-44FE-B1AB-94C86504C7C9Q41206891-5CC16CF7-0AE7-48B9-B54A-D790DA0FE2A9Q41839449-E6A97912-C538-4095-96E6-D35E1BF42B40Q41889471-10D0B0A7-81BA-48EA-A86C-4F430F3F2CEEQ42253765-1520FF16-26FD-4B64-9BC0-AA6159792413Q42589893-D6F73518-6337-47C6-9884-E6F534F0D88BQ42636572-8E383D51-7CE0-4797-871B-CB749CBE6003Q42694315-6957788C-49F6-4A56-9B52-06C21C38871CQ43257559-43C32212-C4B7-4744-9820-5912EF3261DCQ43421449-5CE61C45-F228-4048-90C8-5418653E5A3AQ45236483-34E2BF7C-4924-472C-888C-A3857F6EDAD8Q45952180-B87612B3-AF9B-4024-B848-15B07E87D31EQ46616472-F3F69ADE-BD4A-4509-A9E2-E81DE3B85D75Q46911010-47351E09-6DA9-404F-9E4A-BC14764FE947Q47383863-D56FF0D8-2080-43E1-9745-DCD7A4EDEA94Q48320229-836D0A34-14AB-4988-AE54-A4BB3D73A3A8
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paolo Cravedi
@ast
Paolo Cravedi
@en
Paolo Cravedi
@es
Paolo Cravedi
@nl
type
label
Paolo Cravedi
@ast
Paolo Cravedi
@en
Paolo Cravedi
@es
Paolo Cravedi
@nl
prefLabel
Paolo Cravedi
@ast
Paolo Cravedi
@en
Paolo Cravedi
@es
Paolo Cravedi
@nl
P106
P31
P496
0000-0001-7837-0923